Table 9. Salvage treatment for patients with glioblastoma by KSNO, NCCN, and EANO guideline.
| Guidelines | Salvage treatment | |
|---|---|---|
| KSNO | - Surgical resection of large or symptomatic lesion, if feasible | |
| - Surgically unresectable | ||
| 1) Bevacizumab alone | ||
| 2) Bevacizumab + irinotecan | ||
| 3) Daily temozolomide chemotherapy with low dose | ||
| 4) Lomustine or carmustine | ||
| 5) PCV chemotherapy | ||
| 6) Procarbazine + lomustine | ||
| - Reirradiation | ||
| - Supportive/best care | ||
| - Clinical trial enroll | ||
| NCCN | - Clinical trial enroll | |
| - Surgical resection of large or symptomatic lesion, if feasible | ||
| - Surgically unresectable | ||
| 1) Bevacizumab (alone or combination with carmustine, lomustine, or temozolomide) | ||
| 2) Temozolomide chemotherapy | ||
| 3) Lomustine or carmustine | ||
| 4) PCV chemotherapy | ||
| 5) Regorafenib | ||
| - Reirradiation | ||
| - Supportive/best care | ||
| EANO | - Clinical trial enroll | |
| - Surgical resection of large or symptomatic lesion, if feasible | ||
| - Surgically unresectable | ||
| 1) Bevacizumab | ||
| 2) Nitrosourea regimen | ||
| 3) Temozolomide chemotherapy rechallenge | ||
| - Reirradiation | ||
| - Supportive/best care | ||
EANO, European Association of Neuro-Oncology; KSNO, Korean Society for Neuro-Oncology; NCCN, National Comprehensive Cancer Network; PCV, procarbazine, CCNU, and vincristine